MedTrace Logo

Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level

NCT03488706 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2018-04-05

No results posted yet for this study

Summary

Prostate cancer screening with PSA is plagued by high rate of unnecessary prostate biopsies, especially in the "gray zone" (4.00ng/ml e 10.99ng/ml). We introduce a new circulating-tumor-cell (CTC) biomarker for detection of prostate cancer in patients in the PSA "gray zone" level, with the clinically verified potential to substantially decrease the number of unnecessary prostate biopsies.

Conditions

Sponsors & Collaborators

  • CellMaxLife

    lead INDUSTRY

Principal Investigators

  • Ying-Hsu Chang · Chang Gung Memorial Hospital

Eligibility

Min Age
20 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-17
Primary Completion
2018-12-12
Completion
2021-06-02

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03488706 on ClinicalTrials.gov